Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study

Leukemia & Lymphoma
Jan WalewskiStefan W Henning

Abstract

This open-label, single-arm phase II study examined efficacy, safety, pharmacokinetics, and biomarkers of histone deacetylase (HDAC) inhibitor resminostat in patients with relapsed or refractory Hodgkin lymphoma. Thirty-seven heavily pretreated patients received 600 (19 patients) or 800 mg (18 patients) oral resminostat daily for the initial 5 days of 14-day treatment cycles. Objective response rate (ORR) (primary) was 34% reaching disease control in 54% patients. Most patients (69%) showed reduced tumor size and reduced [18F]-FDG uptake in target lesions (71%). Median progression-free survival (PFS) was 2.3 months (95%CI [1.3; 3.3]) and median overall survival (OS) was 12.5 months (95%CI [9.6; 18.6]). Patients who responded or stabilized under resminostat had a 10-month longer OS than patients who progressed. Efficacy assessment, pharmacodynamics, and exploratory biomarker results followed plasma levels, showed target engagement and epigenetic modulations. Common drug-related adverse events (AEs) were nausea, vomiting, anemia, thrombocytopenia, and fatigue, mainly grade 1 or 2.

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Feb 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H YoungP Price
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Sep 27, 2003·Analytical Biochemistry·Dennis WegenerAndreas Schwienhorst
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Dec 4, 2010·Investigational New Drugs·Daniela Buglio, Anas Younes
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesAndreas Engert
Sep 11, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Angelo de ClaroRichard Pazdur
Sep 26, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·André T BrunettoJohann S de Bono
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sally F BarringtonBruce D Cheson
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Mar 22, 2015·The Journal of the American Academy of Orthopaedic Surgeons·James L Carey, Kevin G Shea
Apr 8, 2015·Cancer Chemotherapy and Pharmacology·Satoru KitazonoTomohide Tamura
Jun 4, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Stathis, A Younes
Jun 15, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yago NietoBorje S Andersson
Oct 28, 2015·American Journal of Hematology·Stephen M Ansell
Jan 21, 2016·Journal of Immunology Research·Roberta FedeleFortunato Morabito
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandCraig H Moskowitz
Dec 20, 2016·Journal of Internal Medicine·I Glimelius, A Diepstra

❮ Previous
Next ❯

Citations

Jul 2, 2020·OncoTargets and Therapy·Shinichi MakitaKensei Tobinai
Feb 23, 2019·Expert Review of Gastroenterology & Hepatology·Jun ZhaoMatthew W Lawless
Feb 29, 2020·Therapeutic Advances in Hematology·Theodoros P VassilakopoulosMaria K Angelopoulou
Oct 24, 2020·British Journal of Haematology·Julia J ScarisbrickPablo L Ortiz-Romero
Apr 24, 2021·Expert Review of Clinical Immunology·Antreas PavlidisEvangelia Papadavid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.